Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188015 · ClinicalTrials.gov registry record · Phase 1
Study of ANX007 in Participants With Primary Open-angle Glaucoma
A Phase 1 study of Open Angle Glaucoma, sponsored by Annexon.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT04188015: Completed Phase 1 study of Open Angle Glaucoma, sponsored by Annexon.
NCT04188015 is a Phase 1 study of Open Angle Glaucoma that has completed, run by Annexon. The registered enrollment target is 17 participants, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04188015, a Phase 1 study of Open Angle Glaucoma, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
Conditions Studied
Interventions
- OTHER Sham Procedure
- BIOLOGICAL 2.5mg ANX007
- BIOLOGICAL 5.0mg ANX007
Study Locations (2)
California
- Eye Research Foundation - Newport Beach
- Stanford Health Care - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2019-06-03 |
| Phase | Phase 1 |
What the finished NCT04188015 record still lists
NCT04188015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 334-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Sham Procedure is the first listed.
NCT04188015 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04188015 about?
NCT04188015 is a clinical study titled "Study of ANX007 in Participants With Primary Open-angle Glaucoma". This is a double-masked, randomized, sham-controlled study evaluating two dose levels of ANX007 vs sham, administered as repeat Intravitreal (IVT) injections in patients with Primary Open-angle Glaucoma.
What is the current status of trial NCT04188015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2018-07-25. Estimated completion is 2019-06-03.
What conditions does trial NCT04188015 study?
This clinical trial studies the following conditions: Open Angle Glaucoma.
What interventions are being tested in trial NCT04188015?
The interventions under investigation include: Sham Procedure (OTHER), 2.5mg ANX007 (BIOLOGICAL), 5.0mg ANX007 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04188015?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04188015 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04188015's enrollment target sits among peer trials
17 28th of 28 higher than 1 of 28 other Open Angle Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
A Study of PER-001 in Participants With Open-Angle Glaucoma
ACTIVE NOT RECRUITING · Phase 1
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI